How myeloid-derived suppressor cells (MDSC) 
Introduction
The tumor environment recruits diverse suppressor cells, such as M2 macrophages, regulatory T cells, and myeloidderived suppressor cells (MDSC; refs. 1-3), to help cancer cells evade the attack by effector cells, leading to the subversion of the immune surveillance (3) . Of the suppressor cells, MDSCs comprise a mixed population of immature myeloid cells that accumulate in various pathologic conditions, particularly in tumors. Recently, the morphologic heterogeneity of MDSCs has been classified by the expression of Ly6C and Ly6G molecules, which has led to the identification of 2 MDSC subsets, i.e., CD11b þ Ly6G þ Ly6C low polymorphonuclear (PMN)-MDSCs and CD11b þ Ly6G À Ly6C high monocytic (Mo)-MDSCs (4) . MDSCs use multiple mechanisms to suppress the adaptive and innate immune systems and increased numbers of MDSCs correlate with a poor prognosis in patients with cancer (5, 6) . Recent studies have shown that a small number of transcription factors regulate aberrant myelopoiesis, leading to MDSC expansion (7) (8) (9) . Despite the advances in the field, the MDSC developmental pathway remains in part elusive.
In contrast with MDSCs, natural killer (NK) cells present barriers to various tumors (10) . NK cell depletion leads to enhanced tumor growth in a mouse tumor model, indicating clearly the involvement of NK cells in tumor surveillance (11) . In addition, it has been shown that improved disease prognosis is associated with the extent of NK cell infiltration in nonsmall cell lung carcinomas and colorectal cancers (12) . However, in a number of cases, NK cells in the tumor environment exhibit maturation and functional defects, decreasing the absolute number of cells (13) (14) (15) . Although a number of studies are underway to determine the cause of NK cell abnormalities, further investigations will be required.
In this study, we describe the unprecedented phenomenon that conventional NK cells in a specific maturation state in the tumor environment are converted into MDSCs in tumorbearing mice. The number of NK cells decreased significantly as the implanted tumor grows, which may be attributed to the conversion of CD11b high CD27 high NK cells into MDSCs rather than being matured into CD11b high CD27 low phenotype. NK cell-activating cytokine, interleukin (IL)-2, inhibited the development of MDSCs from NK cells in vitro and in vivo. Overall, in vivo IL-2 treatment induced NK cell expansion, augmented the activity of the cells, and may result in the regression of tumor growth.
from Charles River Laboratories and C57BL/6 CD45.1 congenic mice were purchased from JAX. The mice were bred and maintained in the Animal Facility for Pharmaceutical Research at Seoul National University under specific pathogen-free conditions.
CT26 colon adenocarcinoma cell line, EL4 lymphoma cell line, and TC-1 lung carcinoma were obtained from the American Type Culture Collection. Human Her-2/neu-expressing transfectoma Her-2/CT26 cells were developed by transduction of CT26 using a retroviral vector system (16, 17) . Cells were maintained in Dulbecco's Modified Eagle Medium or RPMI-1640 medium supplemented with 10% heat-inactivated FBS, 1% penicillin-streptomycin (G418 was supplemented for transfectoma). Cell lines were periodically authenticated by morphologic inspection and passaged for not more than 3 to 4 weeks from thawing.
Antibodies and flow cytometry
Anti-CD11b, CD27-APC, anti-Ly6G-PE/Cy7 (BioLegend), anti-F4/80, CD4 (eBioscience), CD11c (BD Biosciences), CD14, CD49b, CD8, B220, NK1.1, NKp46-PE, anti-CD3, CD19, Gr1-PerCP/Cy5.5, anti-CD122, CD45.1, Ly6C-FITC, and anti-CD45.2-PacificBlue (BioLegend) antibodies were used. IL-2-neutralizing Ab and IL-2-receptor b-blocking Ab were obtained from S4B6 and TMb1 hybridomas, respectively, and were kind gifts from Charles D. Surh (Scripps Institute, La Jolla, California). To analyze the stained cells, FACSCalibur (BD Biosciences) instrument and FlowJo (Treestar) were used.
In vitro T-cell suppression assay
The DO11.10 cells (1 Â 10 5 /well) were stimulated with OVA protein (grade V; Sigma-Aldrich) and were cocultured with or without cytokine-induced MDSCs for 72 hours. For the final 20 to 24 hours, we added 1 mCi per well [ 3 H]-thymidine. The incorporation of the [ 3 H]-thymidine into the divided cells was detected using a liquid scintillation counter (Wallac).
ROS production, arginase 1 activity, and NO production For ROS detection, cells were incubated in the presence of 2.5 mmol/L DCFDA AE 30 ng/mL phorbol 12-myristate 13-acetate (PMA) for 30 minutes. The fluorescence intensity of DCFDA was analyzed by flow cytometry.
Cells were incubated with 2 ng/mL IFN-g and 100 ng/mL lipopolysaccharide (LPS) for 18 hours. To detect NO production, supernatants were collected and mixed with equal volumes of Greiss reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% N-1-naphthylethylenediamine dihydrochloride in DW), after 10 minutes the absorbance at 540 nm was measured. The concentrations were determined by the standard curve of serial dilution of sodium nitrite. Arginase 1 activity was measured in cell lysates (lysed with 0.1% Triton X-100). Subsequently, 50 mL of 10 mmol/L MnCl 2 , 50 mmol/L Tris/HCl were added and the enzyme was activated by heating for 10 minutes at 55 C. Arginine hydrolysis was conducted by incubating the lysates with 0.5 mol/L arginine (pH 9.7) at 37 C for 80 minutes. The reaction was stopped with 400 mL of acid mixture (H 2 SO 4 /H 3 PO 4 /H 2 O ¼ 1/3/7). Urea production was measured at 540 nm after addition of 9% a-isonitrosopropiophenone (control absorbance subtracted from specific absorbance).
In vivo IL-2/aIL-2 Ab complex (IL-2 complex) treatment
To verify the effect of IL-2 on MDSC accumulation and function in vivo, we used an IL-2 complex. Mice received an intraperitoneal injection of 1.5 mg rmIL-2 plus 50 mg aIL-2 antibody. Before injection, rmIL-2 and the aIL-2 Ab were mixed and incubated at room temperature for 15 minutes.
Tumor model and isolation of tumor-infiltrating lymphocytes C57BL/6 mice were injected subcutaneously with 2 Â 10 5 TC-1 tumor cells. Injection of IL-2 complex began on day 1 after tumor injection. IL-2 complex treatment was administered every other day for a total of 5 or 10 times. The volume of the implanted tumor was evaluated for 19 days following the subcutaneous tumor inoculation. To separate the tumor-infiltrating lymphocytes, the tumors were collected and weighed and single-cell suspensions were prepared. The tumor was cut into small pieces and was incubated at 37 C for 0.5 hours in RPMI-1640 containing 1 mg/mL collagenase (Roche), 500 mg/mL DNase I, and 25 mg/mL hyaluronidase (Sigma).
Cell sorting
To sort CD49b þ cells, splenocytes were prepared from tumor-bearing mice. To enrich the desired cell population, CD4 
Statistical analysis
Statistical analyses were conducted using Student t test. The results with values of P < 0.05 were considered to be statistically significant.
Results
Inverse relationship between the percentage of CD11b 
Ly6G
À Ly6C neg/low cells and MDSCs reveals the conversion of NK-phenotype cells into MDSCs.
To explore the development of tumor-associated MDSCs, we used animal models of Her-2-expressing CT26 colon carcinoma and EL4 thymoma. When these tumor cells were subcutaneously inoculated into mice, we observed that the percentage of Ly6C neg/low cells (R1) among CD11b þ population gradually declined in the spleen during tumor progression (Supplementary Fig. S1A and S1B Supplementary Fig. S2A ). Considering the number of live converted cells and the proportions of Ly6C high /Ly6G high cells after incubation, granulocyte macrophage colony-stimulating factor (GM-CSF) was the most efficient cytokine at converting Ly6C neg/low cells into MDSCs in vitro ( Supplementary Fig. S2B and S2C) .
Flow cytometric analysis revealed that the majority of CD11b þ Ly6G À Ly6C neg/low cells expressed CD49b, but not CD14, CD11c, CD4, CD8, and B220 ( Supplementary Fig. S2D) To further investigate the observed conversion of NK cells into MDSC-like cells, we examined whether IL-2 affects this process, as this cytokine activates NK cells and potentiates NK cell-mediated antitumor activity. Notably, addition of IL-2 not only inhibited the expression of Ly6C and Ly6G triggered by GM-CSF, but also maintained the expression of NK cell-markers NK1.1, CD49b, and NKp46 (Fig. 1A) .
To further investigate the role of IL-2 in vivo, NK1. were increased among tumor-infiltrating leukocytes (Fig. 3C ). However, IL-2 cessation reaccelerated the tumor growth, Ly6C high MDSCs were also replenished and, importantly, NK1.1 þ cells were decreased in the tumor bed (Fig. 3C ). In the spleen, the IL-2 counteracting effect on the frequency of MDSCs and NK cells was also prominent, although it did not have a significant effect on the cell numbers ( Fig. 3D and E). This can be explained by previous studies showing that IL-2 directly or indirectly enhances the survival of granulocytes and monocytes (20) (21) (22) . tumor-bearing mice and 7% in the 3-week tumor-bearing mice in the presence of GM-CSF and IL-2 (Fig. 4A ). These data indicate that NK cells may enter a conversion state that is biased toward MDSCs in the tumor environment. The change in responsiveness to IL-2 was further shown by analyzing the related-cytokine receptors. CD49b þ cells from the 5-week tumor-bearing mice preferentially expressed GM-CSF-receptor b-chain (CD131), whereas the expression of IL-2-receptor b-chain (CD122) was decreased compared with the expression in the na€ ve or the 3-week tumor-bearing mice. The expression of GM-CSF-receptor a-chain (CD116) did not increase significantly in the 5-week tumor-bearing mice (Fig.  4B) . Although the expression of Nfil3, an essential regulator of NK cell development (23, 24) , was decreased, the expression levels of Cebpa and Pu.1, essential transcription factors for granulocyte and monocyte development (25, 26) , were significantly increased in CD49b þ cells from the 5-week tumorbearing mice compared with the na€ ve mice (Fig. 4B) . To delineate whether the conversion was driven by these transcription factors, we analyzed the kinetics of gene expression during the cytokine stimulation. The expression of both genes was significantly downregulated, as early as 6 hours after IL-2/ GM-CSF stimulation, compared with the stimulation with GM-CSF alone. The gap in the gene expression level was sustained at all the time points examined. The greatest difference was observed early for Cebpa expression and at a later time-point for Pu.1 (Fig. 4C) . These results suggest that the sustained expression of Cebpa and Pu.1 in the presence of GM-CSF may stimulated with 2 ng/mL IFN-g and 100 ng/mL LPS for 18 hours, supernatants were collected, and nitrite concentration was measured (D). Arginase 1 activity (urea production) was measured in cell lysates (E).
drive the conversion of NK-phenotype cells. However, further investigation will be needed to provide direct evidence for this hypothesis.
CD11b high CD27 high subset of NK cells is converted into MDSCs in tumor-bearing mice
Despite prominent difference in the responsiveness to GM-CSF, we observed no significant difference in the expression of surface/transcription markers related to the lineage specification, NK cell receptors, the secretion of effector/suppressive cytokines between NK cells from naive and tumor-bearing mice (data not shown). To provide more definitive evidence for which NK cells in the tumor environment were converted into MDSCs, we further analyzed the difference in the extent of NK cell maturation based on CD11b/CD27 expression (27) between the na€ ve and tumor-bearing mice. The numbers of total NK cells were significantly decreased in the spleen and bone marrow of the mice inoculated with tumor cells for 3 weeks compared with na€ ve mice ( Fig. 5A and B) . Importantly, the numbers of CD11b high CD27
high and CD11b high CD27 low subsets among NK cells were significantly reduced in tumorbearing mice compared with na€ ve mice, whereas those of the other subsets were relatively similar ( Fig. 5C and D) .
To elucidate whether the reduction of those NK cell populations was attributed to the observed conversion, we separated the lineage Fig. S5C ), of which Fig. S5D ). The expression of CD122, NKp46, and NK1.1 was downregulated in the presence of GM-CSF alone, whereas retained in GM-CSF/IL-2 ( Fig. 6A and B) . The morphology of the CD11b high CD27 high population was similar to the other populations of NK cells and the na€ ve CD11b high CD27
high NK cells, which exhibited a shape consistent with lymphocytes (Supplementary Fig. S4C ). In contrast, ring-, segmented band-, and monocyte-shaped cells were observed after in vitro stimulation with GM-CSF. In the presence of GM-CSF/IL-2, the cells exhibited the morphology of activated NK cells (Fig. 6C) . Another NK-activating cytokine, IL-15, also exerted an inhibitory effect on conversion upon addition of low (20 ng/mL) and high (50 ng/mL) concentrations, although low levels of CD11b 
Gr1
þ cells (1.2%) were present after the addition of lowconcentration of IL-15 (Fig. 6D) .
To show this phenomenon in vivo, we purified CD45.2 þ CD27 high NK cells from tumor-bearing mice and transferred the cells into congenic CD45.1 mice. In tumor-bearing recipients, 12% of the transferred cells were converted into CD11b þ Gr1 þ MDSC phenotype ( Fig. 7A and B) . In addition, the expression of CD122 and NK1.1 was decreased. In contrast, the phenotype of CD27 high NK cells was retained in na€ ve high NK cells was reduced significantly in tumor-bearing recipients compared with na€ ve recipients ( Fig. 7C-E) .
However, endogenous MDSCs may cause cell death of transferred CD27 high NK cells, by which the matured NK cells were reduced. To investigate this, we evaluated the cell death of donor cells. The frequency of Annexin V þ donor cells tended to increase in the tumor-bearing host compared with the na€ ve host, although the difference was not statistically significant ( Supplementary Fig. S6A ). To examine whether MDSCs rendered donor NK cells apoptotic, we transferred MDSCs (4 Â 10 6 / injection) into naive recipients 1 day before and after NK cell transfer. There was no difference in the frequency of apoptotic donor cells in the MDSC-treated na€ ve hosts compared with the na€ ve hosts (Supplementary Fig. S6A ). In the same experimental setting, the donor cells were significantly more converted into MDSCs in the tumor-bearing hosts than in the na€ ve or MDSC-treated na€ ve hosts ( Supplementary Fig. S6B ). To more directly clarify the effect of MDSCs on NK cells during maturation, we stimulated CD45.2 þ CD27 high NK cells with IL-12, -15, and -18 to mature them in vitro (Supplementary Fig.  S6C; ref. 28 ). These cytokines preferentially upregulated the expression of KLRG1 and CD11b, maturation markers for NK cells, compared with the untreated NK cells. However, no differences were observed in the maturation and apoptosis of NK cells even when CD45. compared with other conditions. These results suggested that the reduction of NK cells could be attributed to their conversion into MDSCs, and possibly cell death, in the tumor environment. However, the viability and maturation of NK cells did not seem to be influenced by endogenous MDSCs, at least in the EL4 tumor model.
Discussion
The importance of NK cells for eradicating cancer cannot be overemphasized. Several studies have reported that the tumor environment impairs the development and function of NK cells (13, 15) and even diminishes the number of NK cells in patients with chronic myelogenous leukemia (14) . In this study, we determined that NK cells at a specific maturation stage were converted into immunosuppressive MDSCs, a process that was impeded by IL-2 in vitro and in vivo. Fig. S6 ).
Adoptively transferred NK cells lost NK markers and converted into MDSCs probably by tumor-derived GM-CSF, assumed by in vitro conversion assay shown in this study. Nevertheless, the conversion could be regulated by various cytokines released by tumor. We are supposed to clarify this by tumor cell knockdown experiments using shRNA or neutralization of cytokines in future studies.
Because the exact roles of CD27 in NK cell biology have not been fully investigated, it aroused our curiosity whether CD27-CD27 ligand signaling influenced NK cells or MDSCs. However, upon CD27-mediated signaling by the addition of recombinant ligands in vitro, no remarkable effect was found other than increased apoptosis during the conversion of NK cells into MDSCs (data not shown), although the ligands may play other roles in vivo.
We showed that the conversion of Lin S4C ). Nevertheless, NK cells in the other maturation states were not converted, indicating that this phenomenon was not because of the myeloid-biased differentiation by the tumor environment, rather NK cells in a specific maturation state were converted into MDSCs. Several studies have endeavored to explain the development, function, migration, and fate of MDSCs (31) (32) (33) . A recently published study has determined that the myeloid precursors of MDSCs that reside in the spleen are relocated to tumors (34, 35) . Moreover, novel transdifferentiation pathway from monocytic-to-granulocytic MDSCs driven by epigenetic regulation in the tumor environment, which is beside the classical divergent development of monocytes and granulocytes, has been revealed (33) . From a different perspective, we suggest that NKphenotype cells could be additional precursors of MDSCs. Accordingly, the precise contribution of NK cells to MDSC expansion must be examined; however, the depletion of NK cells by antibodies did not significantly influence the accumulation of MDSCs in the tumor-bearing mice (data not shown). Apart from the question of contribution, the observation that the effector NK cells were converted into suppressor cells indicated the aggravation of the immunosuppressive environment in the tumor-bearing mice, which may also apply to patients with cancer (14) .
We have attempted to identify the conversion of NK cells into MDSCs in a human system. Several studies have shown that MDSCs can be produced from whole PBMCs and monocytes (36) (37) (38) (39) (49, 50) . We showed that IL-2 prevented NK cells from converting into MDSCs in vitro and in vivo. However, no significant inhibitory effect on the number of MDSCs was observed in the spleen of IL-2 complex-treated tumor-bearing mice. A previous study reported that the cytokines produced from IL-2-activated NK cells prolongs the survival of granulocytes and monocytes (22) and IL-2 complex strongly activates NK cells (18) . In this case, the effect on MDSC numbers in IL-2 complex-treated mice could be underestimated because of the increase in granulocytes/monocytes, which share surface markers, such as Ly6C, Ly6G, CD11b, with PMN-and MoMDSCs. Collectively, the data in this study suggest that NK cell reduction resulted from the conversion of NK cells into MDSCs in the middle of the maturation stage, before CD11b high CD27
high NK cells give rise to the mature CD11b high CD27 low phenotype in the tumor environment. It could be a missing part of mechanisms by which results in NK cell reduction in tumor immunosuppressive environment, suggesting a novel tumor evasion mechanism. It is also noteworthy that our data suggested the possibility of conversion between lymphoid (NK cells) and myeloid cells (MDSCs), which are derived from distinct progenitor cells.
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